Atara Biotherapeutics, Inc. - Common Stock (ATRA) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2014 to Q3 2025

Type / Class
Equity / Common Stock
Symbol
ATRA on Nasdaq
Shares outstanding
8,165,808
Price per share
$14.33
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
15
Total reported value
$215
% of total 13F portfolios
0%
Share change
+15
Value change
+$215
Number of holders
1
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Atara Biotherapeutics, Inc. - Common Stock (ATRA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Panacea Innovation Ltd 20% -0.05% -$1,154,619 1,632,345 -4.7% Panacea Innovation Limited 12 Jan 2026
Adiumentum Capital Fund I LP 20% 1,370,081 Adiumentum Capital Fund I LP 14 May 2025

As of 30 Sep 2025, 1 institutional investors reported holding 15 shares of Atara Biotherapeutics, Inc. - Common Stock (ATRA). This represents 0% of the company’s total 8,165,808 outstanding shares.

Institutional Holders of Atara Biotherapeutics, Inc. - Common Stock (ATRA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 15 $215 +$215 $14.33 1
2025 Q1 0 $0 -$839 $14.33 0
2024 Q4 63 $839 $13.32 2
2024 Q3 35 $285 -$1,511,256 $8.14 1
2024 Q2 182,077 $1,511,600 -$88,625,978 $8.50 5
2024 Q1 83,252,102 $57,777,566 +$13,851,989 $0.69 80
2023 Q4 51,978 $26,654 -$34,501 $0.51 2
2023 Q3 85,366,944 $126,342,685 -$2,697,551 $1.48 106
2023 Q2 89,634,059 $144,308,326 -$25,953,820 $1.61 113
2023 Q1 102,669,151 $297,703,409 +$14,378,402 $2.90 122
2022 Q4 97,305,217 $319,156,676 -$2,299,642 $3.28 134
2022 Q3 90,403,280 $341,734,216 -$18,524,369 $3.78 142
2022 Q2 87,744,670 $683,413,623 +$4,019,124 $7.79 128
2022 Q1 97,854,986 $909,198,182 +$12,542,571 $9.29 137
2021 Q4 92,514,258 $1,458,089,510 +$80,394,436 $15.76 131
2021 Q3 89,699,071 $1,572,026,770 +$68,639,242 $17.90 139
2021 Q2 85,974,550 $1,307,818,163 +$14,820,006 $15.55 144
2021 Q1 86,114,767 $1,236,597,081 -$11,291,963 $14.36 148
2020 Q4 82,495,390 $1,619,419,375 +$50,632,531 $19.63 141
2020 Q3 82,444,744 $1,069,165,081 +$62,280,208 $12.96 135
2020 Q2 76,393,987 $1,113,025,589 +$284,434,115 $14.57 116
2020 Q1 59,733,492 $507,433,632 +$1,171,045 $8.51 102
2019 Q4 58,187,250 $958,332,660 +$38,679,395 $16.47 110
2019 Q3 56,046,029 $791,338,512 +$104,558,817 $14.12 106
2019 Q2 50,271,348 $1,011,212,530 +$23,222,311 $20.11 113
2019 Q1 48,808,749 $1,940,159,733 +$25,043,891 $39.75 117
2018 Q4 48,248,312 $1,676,102,014 +$62,556,812 $34.74 118
2018 Q3 46,348,347 $1,916,490,444 -$3,168,580 $41.35 114
2018 Q2 46,455,501 $1,707,224,921 +$110,906,473 $36.75 122
2018 Q1 43,359,221 $1,688,258,623 +$554,643,868 $39.00 112
2017 Q4 29,766,797 $540,570,369 +$34,897,826 $18.10 81
2017 Q3 26,588,544 $441,130,415 +$15,311,746 $16.55 80
2017 Q2 25,710,565 $359,951,428 +$19,475,912 $14.00 78
2017 Q1 23,968,878 $492,550,713 +$57,012,769 $20.55 81
2016 Q4 23,188,198 $329,269,488 +$7,518,777 $14.20 81
2016 Q3 22,393,280 $478,869,785 +$15,359,285 $21.39 71
2016 Q2 21,590,215 $485,998,073 +$46,726,523 $22.51 69
2016 Q1 19,798,948 $376,742,000 +$7,108,410 $19.03 68
2015 Q4 19,264,140 $508,636,288 -$20,899,576 $26.41 83
2015 Q3 19,466,451 $612,023,952 +$193,338,473 $31.44 86
2015 Q2 13,106,859 $691,496,994 +$108,403,349 $52.76 74
2015 Q1 11,227,473 $461,513,969 +$185,585,252 $41.57 52
2014 Q4 6,725,410 $172,103,401 +$161,930,625 $26.75 39